ArriVent BioPharma (NASDAQ:AVBP) Announces Earnings Results

ArriVent BioPharma (NASDAQ:AVBP) posted its earnings results on Monday. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24, FiscalAI reports. The firm had revenue of $5.00 million during the quarter, compared to the consensus estimate of $0.80 million.

ArriVent BioPharma Trading Up 2.5%

ArriVent BioPharma stock traded up $0.34 during midday trading on Wednesday, hitting $13.83. The stock had a trading volume of 152,847 shares, compared to its average volume of 743,783. The firm’s fifty day moving average is $22.40 and its two-hundred day moving average is $26.56. The company has a market capitalization of $681.91 million, a PE ratio of -3.85 and a beta of 1.66. ArriVent BioPharma has a 52-week low of $11.36 and a 52-week high of $35.83.

Wall Street Analysts Forecast Growth

A number of analysts have commented on AVBP shares. Citigroup reduced their target price on shares of ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, October 7th. Wall Street Zen upgraded shares of ArriVent BioPharma from a “strong sell” rating to a “sell” rating in a research report on Sunday, October 18th. Truist Financial lifted their price target on shares of ArriVent BioPharma from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of ArriVent BioPharma in a research report on Tuesday, September 22nd. Finally, HC Wainwright cut their price objective on shares of ArriVent BioPharma from $47.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, October 8th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, ArriVent BioPharma presently has an average rating of “Moderate Buy” and a consensus target price of $24.89.

About ArriVent BioPharma

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.